We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+2.81%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$628M
AUM Growth
-$105M
Cap. Flow
-$132M
Cap. Flow %
-21%
Top 10 Hldgs %
31.66%
Holding
141
New
23
Increased
28
Reduced
42
Closed
26

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$23.5M
2
NVMI
Nova
NVMI
+$11.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.99M
4
VKTX icon
Viking Therapeutics
VKTX
+$7.81M
5
CHKP icon
Check Point Software Technologies
CHKP
+$7.36M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$28.3M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
CRM icon
Salesforce
CRM
+$8.64M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.08M
5
ASML icon
ASML
ASML
+$6.31M

Sector Composition

Rank Sector Weight
1 Healthcare 70%
2 Technology 19.18%
3 Consumer Discretionary 3.53%
4 Communication Services 2.96%
5 Utilities 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APRE icon
101
Aprea Therapeutics
APRE
$7.68M
$743K 0.12%
270,000
– –
VIR icon
102
Vir Biotechnology
VIR
$1.46B
$699K 0.11%
93,329
-68,722
-42% -$597K
ELEV
103
DELISTED
Elevation Oncology
ELEV
$648K 0.1%
1,079,762
+749,762
+227% +$1.11M
ADCT icon
104
ADC Therapeutics
ADCT
$134M
$646K 0.1%
205,036
-480,511
-70% -$1.52M
GLUE icon
105
Monte Rosa Therapeutics
GLUE
$1.4B
$626K 0.1%
118,103
-256,897
-69% -$1.3M
FDMT icon
106
4D Molecular Therapeutics
FDMT
$532M
$526K 0.08%
48,702
-193,824
-80% -$3.22M
CGEN icon
107
Compugen
CGEN
$222M
$411K 0.07%
227,094
-512,145
-69% -$935K
TNGX icon
108
Tango Therapeutics
TNGX
$4.43B
$385K 0.06%
+50,000
New +$477K
PRME icon
109
Prime Medicine
PRME
$527M
$296K 0.05%
76,456
-50,968
-40% -$236K
LVTX
110
DELISTED
LAVA Therapeutics
LVTX
$243K 0.04%
146,457
-221,125
-60% -$405K
IMTXW
111
DELISTED
Immatics N.V. Warrants
IMTXW
$230K 0.04%
100,000
– –
SRPT icon
112
CALL
Sarepta Therapeutics
SRPT
$1.57B
$125K 0.02%
1,000
-14,000
-93% -$1.94M
TENX icon
113
Tenax Therapeutics
TENX
$363M
$101K 0.02%
+29,166
New +$106K
ARBE icon
114
Arbe Robotics
ARBE
$80.3M
$82.4K 0.01%
43,165
– –
AKRO
115
DELISTED
Akero Therapeutics
AKRO
– –
-141,620
Closed -$3.32M
AMAT icon
116
Applied Materials
AMAT
$403B
– –
-24,604
Closed -$5.81M
AMLX icon
117
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-36,050
Closed -$68.5K
ARGX icon
118
argenx
ARGX
$53.4B
– –
-1,556
Closed -$669K
ARWR icon
119
Arrowhead Research
ARWR
$11.9B
– –
-48,175
Closed -$1.25M
BBIO icon
120
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-204,600
Closed -$5.18M
CPRX
121
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-288,000
Closed -$4.46M
CRM icon
122
Salesforce
CRM
$151B
– –
-33,600
Closed -$8.64M
FULC icon
123
PUT
Fulcrum Therapeutics
FULC
$273M
– –
-59,000
Closed -$366K
GOSS icon
124
Gossamer Bio
GOSS
$82.9M
– –
-222,134
Closed -$200K
ICL icon
125
ICL Group
ICL
$6.53B
– –
-107,238
Closed -$459K
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2024 Portfolio in Review

As of Q3 2024, Sphera Funds Management held 141 positions worth $628M, down 14% from $733M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Sphera Funds Management withdrew a net $132M in Q3 2024, closing 26 positions and reducing 42 holdings. Its most notable exit was Salesforce, an estimated $8.64M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Nova worth $10.8M.

  • Sphera Funds Management's largest Q3 2024 buy was Nova: 51,960 shares worth $10.8M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2024, an estimated $23.5M increase.
  • Sphera Funds Management's biggest Q3 2024 reduction was Broadcom, cutting an estimated $28.3M.
  • Sphera Funds Management fully exited Salesforce in Q3 2024, selling an estimated $8.64M.
  • Sphera Funds Management's ten largest holdings make up 32% of its $628M portfolio in Q3 2024.
  • Sphera Funds Management opened 23 new positions and closed 26 in Q3 2024.
  • Sphera Funds Management's portfolio value fell 14% quarter-over-quarter to $628M.

Based on Sphera Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.